Payment overview · 2025
General Payments
$1,143.93
74 reported records · 16 companies
Healthcare provider profile · identity verified
Keith T Applegate, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, KY · NPI 1245235795
Verified facts
What the public records show
CMS Open Payments records show Keith T Applegate, M.D. received $1,143.93 in general payments during 2025 across 74 reported records.
Amgen Inc. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $271.01 | 23.7% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.26 | 16.5% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.14 | 14.2% | 17 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $86.85 | 7.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.43 | 7.4% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $74.79 | 6.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.88 | 5.7% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $46.37 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.58 | 2.6% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.29 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.79 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.38 | 1.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.15 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.89 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.65 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.47 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,131.51 | 73 |
| Education | $12.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $271.01 | 19 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $223.96 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $152.62 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $152.62 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.08 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.43 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $74.79 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.55 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.19 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.61 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $46.37 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.58 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 32 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
52 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 240 |
| Levothyroxine Sodium | Levothyroxine Sodium | 566 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 556 | 161 |
| Omeprazole | Omeprazole | 475 | 148 |
| Lisinopril | Lisinopril | 443 | 139 |
| Losartan Potassium | Losartan Potassium | 350 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 346 | 99 |
| Gabapentin | Gabapentin | 334 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 304 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 89 |
| Simvastatin | Simvastatin | 256 | 75 |
| Metformin Hcl | Metformin Hcl | 251 | 77 |
| Furosemide | Furosemide | 249 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 51 |
| Meloxicam | Meloxicam | 239 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 70 |
| Tramadol Hcl | Tramadol Hcl | 228 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 70 |
| Sertraline Hcl | Sertraline Hcl | 214 | 69 |
| Alprazolam | Alprazolam | 213 | 36 |
| Glimepiride | Glimepiride | 208 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 63 |
| Allopurinol | Allopurinol | 187 | 55 |
| Metformin Hcl Er | Metformin Hcl | 181 | 54 |
| Donepezil Hcl | Donepezil Hcl | 180 | 56 |
| Carvedilol | Carvedilol | 177 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 53 |
| Potassium Chloride | Potassium Chloride | 161 | 46 |
| Doxycycline Hyclate | Doxycycline Hyclate | 152 | 127 |
| Doxazosin Mesylate | Doxazosin Mesylate | 147 | 45 |
| Lorazepam | Lorazepam | 147 | 24 |
| Famotidine | Famotidine | 146 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 40 |
| Methylprednisolone | Methylprednisolone | 134 | 126 |
| Ozempic | Semaglutide | 133 | 25 |
| Trazodone Hcl | Trazodone Hcl | 124 | 41 |
| Baclofen | Baclofen | 121 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 61 |
| Bupropion Xl | Bupropion Hcl | 118 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 35 |
| Eliquis | Apixaban | 118 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 30 |
| Synthroid | Levothyroxine Sodium | 105 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 25 |
| Celecoxib | Celecoxib | 98 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 28 |
| Atenolol | Atenolol | 93 | 26 |
| Montelukast Sodium | Montelukast Sodium | 91 | 30 |
| Jardiance | Empagliflozin | 90 | 25 |
| Alendronate Sodium | Alendronate Sodium | 88 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 46 |
| Ezetimibe | Ezetimibe | 85 | 23 |
| Mirtazapine | Mirtazapine | 84 | 29 |
| Lansoprazole | Lansoprazole | 83 | 29 |
| Buspirone Hcl | Buspirone Hcl | 78 | 30 |
| Memantine Hcl | Memantine Hcl | 77 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 28 |
| Spironolactone | Spironolactone | 71 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 60 |
| Mounjaro | Tirzepatide | 69 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 31 |
| Finasteride | Finasteride | 65 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 18 |
| Xarelto | Rivaroxaban | 65 | 16 |
| Azithromycin | Azithromycin | 64 | 63 |
| Pregabalin | Pregabalin | 62 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 14 |
| Warfarin Sodium | Warfarin Sodium | 60 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 16 |
| Diazepam | Diazepam | 53 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 43 |
| Prednisone | Prednisone | 53 | 34 |
| Temazepam | Temazepam | 53 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 52 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | 11 |
| Naproxen | Naproxen | 45 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 14 |
| Sulindac | Sulindac | 41 | 20 |
| Chlorthalidone | Chlorthalidone | 40 | 11 |
| Imipramine Hcl | Imipramine Hcl | 40 | 12 |
| Bumetanide | Bumetanide | 39 | 11 |
| Fluconazole | Fluconazole | 39 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Colestipol Hcl | Colestipol Hcl | 37 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 35 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Estradiol | Estradiol | 34 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | 11 |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Glipizide | Glipizide | 30 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 17 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Ciclopirox | Ciclopirox Olamine | 16 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 15 |
| Colchicine | Colchicine | 16 | 12 |
| Fluocinonide | Fluocinonide | 16 | 13 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Valsartan | Valsartan | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Sotalol Af | Sotalol Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,143.93 · 74 records | Amgen Inc. | ABRYSVO, AIRSUPRA, BEXSERO, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, Fluad, Flucelvax, GIVLAARI, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PEDIARIX, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VYNDAMAX, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error